For a Vietnamese pharmaceutical manufacturer planning EU market entry, the most expensive question is not, “Can this site pass an EU GMP inspection?”
It is this: Can the existing facility support the intended product and EU supply model without creating an open-ended remediation programme, an unmanageable shutdown, or stranded CAPEX?
That distinction matters. A conventional…
